Intercept Pharmaceuticals (NASDAQ:ICPT) has been given a $74.00 target price by equities research analysts at Citigroup in a note issued to investors on Thursday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Citigroup’s price target suggests a potential upside of 17.74% from the company’s previous close.

Several other equities analysts have also commented on ICPT. Cowen restated an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. Goldman Sachs Group reiterated a “neutral” rating and issued a $79.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Finally, Leerink Swann lowered their price target on Intercept Pharmaceuticals from $120.00 to $66.00 and set a “market perform” rating for the company in a report on Saturday, September 23rd. Four research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $141.58.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $62.85 on Thursday. Intercept Pharmaceuticals has a 52-week low of $54.98 and a 52-week high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. During the same period last year, the company earned ($3.59) earnings per share. Intercept Pharmaceuticals’s revenue was up 697.9% on a year-over-year basis. equities analysts anticipate that Intercept Pharmaceuticals will post -13.35 EPS for the current fiscal year.

In other news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 2,566 shares of company stock worth $151,025. 9.20% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Public Employees Retirement Association of Colorado lifted its position in Intercept Pharmaceuticals by 1.1% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 43 shares during the period. WFG Advisors LP lifted its position in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the period. Utah Retirement Systems lifted its position in Intercept Pharmaceuticals by 6.5% during the 2nd quarter. Utah Retirement Systems now owns 3,300 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 200 shares during the period. State of Wisconsin Investment Board lifted its position in Intercept Pharmaceuticals by 7.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 3,567 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 260 shares during the period. Finally, Voya Investment Management LLC lifted its position in Intercept Pharmaceuticals by 4.7% during the 2nd quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock worth $847,000 after acquiring an additional 313 shares during the period. 73.76% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/citigroup-reiterates-74-00-price-target-for-intercept-pharmaceuticals-icpt/1776022.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.